Leading International Investment Research

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Leading International Investment Research, Edison Investment Research

Equity Bottom-Up

<p>Probiodrug presented the first data from its flagship Phase IIa clinical trial with its lead drug candidate PQ912, a glutaminyl cyclase (QC) inhibitor, for early Alzheimer&rsquo;s disease (AD) patients. Overall, we find the data positive, with several secondary endpoints and exploratory clinical tests especially piquing our interest. Our valuation is increased to &euro;487m or &euro;60/share.</p>

Probiodrug presented the first data from its flagship Phase IIa clinical trial with its lead drug candidate PQ912, a glutaminyl cyclase (QC) inhibitor, for early Alzheimer&rsquo;s disease (AD) patients. Overall, we find the data positive, with several secondary endpoints and exploratory clinical tests especially piquing our interest. Our valuation is increased to &euro;487m or &euro;60/share.

First data paint a positive overall picture

Probiodrug AG

First data paint a positive overall picture